Skip to content

You are using a browser that is not supported by this site. The site will not function properly. Please switch to the latest version of a supported browser such as Chrome, Safari, Edge, or Firefox to use this site.

PAH progression makes it essential to evaluate patient risk regularly1-4

Progression can happen rapidly, even in patients early in their disease1

PAH is characterized by worsening cardiopulmonary hemodynamics and right ventricle function, ultimately leading to right heart failure1,2

In the REVEAL Registry,43%of FC II patients experienced
clinical worsening
within 1 year,
similar to that of FC III patients (45%)1

In patients with FC I/II disease,
survival rates were78%(95% CI, 73%-83%)
at 3 years
vs 55% in FC III/IV patients5

Assess risk regularly in PAH, with a goal of achieving low risk3,4

  • Assessing risk criteria can help determine if proactive treatment changes need to be considered3,4
Select 2015 ESC/ERS Guidelines Recommendations
For patients with an inadequate response to therapy, treatment escalation may be considered3
The use of oral prostacyclin therapy is recommended as 1 option to help achieve low-risk status3
Learn more about Treating PAH

Important Safety Information

Contraindications

  • Avoid use of Orenitram in patients with severe hepatic impairment (Child Pugh Class C) due to increases in systemic exposure.

Warnings and Precautions

  • Abrupt discontinuation or sudden large reductions in dosage of Orenitram may result in worsening of PAH symptoms.
  • The Orenitram tablet shell does not dissolve. In patients with diverticulosis, Orenitram tablets can lodge in a diverticulum.

Adverse Reactions

  • In the 12-week, placebo-controlled, monotherapy study, and an event-driven, placebo-controlled, combination therapy study, adverse reactions that occurred at rates at least 5% higher on Orenitram than on placebo included headache, diarrhea, nausea, vomiting, flushing, pain in jaw, pain in extremity, hypokalemia, abdominal discomfort, and upper abdominal pain.

Drug Interactions

  • Co-administration of Orenitram and the CYP2C8 enzyme inhibitor gemfibrozil increases exposure to treprostinil; therefore, Orenitram dosage reduction may be necessary in these patients.

Specific Populations

  • Animal reproductive studies with Orenitram have shown an adverse effect on the fetus. There are no adequate and well-controlled studies with Orenitram in pregnant women.
  • It is not known whether treprostinil is excreted in human milk or if it affects the breastfed infant or milk production.
  • Safety and effectiveness of Orenitram in pediatric patients have not been established.
  • Use of Orenitram in patients aged 65 years and over demonstrated slightly higher absolute and relative adverse event rates compared to younger patients. Caution should be used when selecting a dose for geriatric patients.
  • There is a marked increase in the systemic exposure to treprostinil in hepatically impaired patients.

Indication

Orenitram is a prostacyclin mimetic indicated for treatment of pulmonary arterial hypertension (PAH) (WHO Group 1) to delay disease progression and to improve exercise capacity. The studies that established effectiveness included predominately patients with WHO functional class II-III symptoms and etiologies of idiopathic or heritable PAH (66%) or PAH associated with connective tissue disease (26%).

OREISIhcpOCT19

Please see Full Prescribing Information and Patient Information for Orenitram.

For additional information, call 1-877-UNITHER (1-877-864-8437).

CI=confidence interval; ERS=European Respiratory Society; ESC=European Society of Cardiology; FC=functional class; PAH=pulmonary arterial hypertension; REVEAL=Registry to Evaluate Early and Long-Term PAH Disease Management.

References: 1. Frost AE, Badesch DB, Miller DP, et al. Evaluation of the predictive value of a clinical worsening definition using 2-year outcomes in patients with pulmonary arterial hypertension: a REVEAL Registry analysis. Chest. 2013;144(5):1521-1529. 2. Champion HC, Michelakis ED, Hassoun PM. Comprehensive invasive and noninvasive approach to the right ventricle—pulmonary circulation unit: state of the art and clinical and research implications. Circulation. 2009;120(11):992-1007. 3. Galiè N, Humbert M, Vachiery JL, et al. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: the Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS). Eur Respir J. 2015;46(4):903-975. 4. Benza RL, Gomberg-Maitland M, Elliott CG, et al. Predicting survival in patients with pulmonary arterial hypertension: the REVEAL risk score calculator 2.0 and comparison with ESC/ERS-based risk assessment strategies. Chest. 2019;156(2):323-337. 5. Kim NH, Fisher M, Poch DS, et al. Long-term outcomes in pulmonary arterial hypertension by functional class: a meta-analysis of randomized controlled trials and observational registries. J Heart Lung Transplant. 2019;38(4)(suppl):S96-S97.